Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Sanofi's Tzield (teplizumab) wins FDA label expansion for stage 3 type 1 diabetes in pediatric patients via Ph3 data
Antibody, autoimmune, monoclonal antibody, type 1 diabetes, pediatric patients - Read more

FDA approves Merck & Co.'s Welireg (belzutifan) plus Keytruda (pembrolizumab) combo for adjuvant clear cell renal cell carcinoma based on Ph3 results
Small molecule, antibody, cancer, renal cell carcinoma, PD-1 inhibitor, HIF-2α inhibitor -Read more

AstraZeneca's Truqap (capivasertib) wins FDA approval for PTEN-deficient metastatic prostate cancer following Ph3 data
Small molecule, cancer, AKT inhibitor, prostate cancer, PTEN deficiency, companion diagnostic - Read more

ALK's EURneffy (adrenaline) receives MHRA approval for anaphylaxis in children aged 4 and older weighing 15–30 kg
Small molecule, autoimmune, adrenaline, anaphylaxis, pediatric patients, needle-free delivery - Read more

Bayer's Ambelvist (gadoquatrane) receives FDA approval for contrast-enhanced MRI to detect lesions in central nervous system and non-central nervous system body regions
Diagnostic imaging agent, neurological, gadolinium-based contrast agent, MRI contrast, CNS lesions, pediatric patients - Read more

Rocket Pharmaceuticals sells rare paediatric disease priority review voucher for $180M
Voucher sale, rare disease, gene therapy, priority review voucher - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

Johnson & Johnson's Talvey (talquetamab) plus Darzalex Faspro (daratumumab) combo demonstrates Ph3 superiority in relapsed or refractory multiple myeloma
Antibody, cancer, bispecific antibody, multiple myeloma, GPRC5D, combination therapy - Read more

Eli Lilly's Jaypirca (pirtobrutinib) combo cuts progression risk by nearly half in Ph3 chronic lymphocytic leukemia study
Small molecule, cancer, BTK inhibitor, chronic lymphocytic leukemia, combination therapy - Read more

Eli Lilly's (AJI-11095) JAK2 inhibitor shows early efficacy in Ph1 myelofibrosis study
Small molecule, cancer, JAK2 inhibitor, myelofibrosis, hematologic malignancy - Read more

Rhythm Pharmaceuticals' Imcivree (setmelanotide) shows encouraging BMI reductions in Ph2 Prader-Willi syndrome study
Small molecule, metabolic, obesity, Prader-Willi syndrome, melanocortin-4 receptor agonist, rare genetic disease - Read more

Celltrion, Abpro Holdings' CT-P72 enters Ph1 trials targeting HER2 for solid tumors including bladder, biliary tract and breast cancers
Antibody, cancer, multispecific antibody, T-cell engager, HER2, solid tumors - Read more

Enterome's (EO2463) Ph1/2 interim data show durable CD8 T cell responses in indolent non-Hodgkin lymphoma
Vaccine, cancer, peptide vaccine, non-Hodgkin lymphoma, CD8 T cell response, combination therapy - Read more

Faron Pharmaceuticals' Bexmarilimab shows 85% overall response rate in Ph1/2 trial for high-risk myelodysplastic syndrome
Antibody, cancer, monoclonal antibody, myelodysplastic syndrome, immunotherapy, Clever-1 target - Read more

SynAct Pharma's resomelagon hits 76.4% ACR20 response in Ph2b trial for rheumatoid arthritis
Small molecule, autoimmune, melanocortin agonist, rheumatoid arthritis, ACR20 response - Read more

HMNC Brain Health raises $50M Series B first closing, advancing neuroscience clinical programs
Neuroscience, clinical-stage, small molecule, treatment-resistant depression, precision medicine - Read more

Kos Biotechnology Partners holds third closing of inaugural global life sciences fund at $123M
Life sciences investment, biotech/novel therapeutics, pharma services, tech-enabled technologies - Read more

Pelago Bioscience acquires RG Discovery, creating integrated biology-chemistry drug discovery CRO platform
Small molecule, drug discovery, strategic, major transaction - Read more

CMS proposes permanent Medicare drug price negotiation framework, expanding program through 2029 and beyond
Medicare drug pricing, small molecule, cost reduction, regulatory - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Soligenix scraps HyBryte (hypericin) cutaneous T-cell lymphoma program after Ph3 failure, explores merger and acquisition options
Small molecule, cancer, photodynamic therapy, cutaneous T-cell lymphoma, synthetic peptide - Read more

Germany health minister defends pharma reforms as Eli Lilly, Boehringer Ingelheim, Pfizer slash investments
Pharmaceutical pricing, healthcare policy, financial, operational - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here